# Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

> **NCT01958970** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pinta Biotherapeutics** · enrollment: 51 (actual)

## Conditions studied

- End Stage Renal Disease
- Kidney Disease
- Protein Energy Wasting

## Interventions

- **DRUG:** PINTA 745
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01958970
- **Lead sponsor:** Pinta Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-11
- **Final completion:** 2016-01
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2018-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958970, "Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01958970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*